On Tuesday, the FDA held a public meeting titled “Administering the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access.”
On Tuesday, the FDA held a public meeting titled “Administering the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access.” The meeting provided an opportunity for the public to submit comments concerning the ways in which the FDA administers the Hatch-Waxman Amendments with respect to prioritizing the approval of generic drugs.
The Hatch-Waxman Act (formally titled The Drug Price Competition and Patent Term Restoration Act) was first implemented in 1984. The act was intended to expedite the approval of generic drugs, provide periods of patent exclusivity, and streamline the litigation process surrounding generic drugs. The FDA called this week’s public meeting to hear comments on how the FDA can help establish a balance between encouraging innovation and facilitating the availability of lower-cost generic drugs for patients.
FDA Commissioner Scott Gottlieb, MD, opened the meeting by noting that too many patients are unable to afford necessary drugs. “FDA doesn’t have a direct role in how drugs are priced,” Gottlieb said, “but at FDA, we do play a key, if indirect, role in the eventual cost of medicines.” He went on to explain that the FDA will seek to reduce prices by ensuring that the agency is efficient, predictable, and science-based with respect to its regulatory requirements, and that it will prioritize price competition among drugs.
Gottlieb also announced that the FDA is developing 2 new documents that will help streamline the Abbreviated New Drug Application (ANDA) process. First, the agency will issue a “Good ANDA Assessment Practices” Manual of Policies and Procedures (MAPP). This document will outline approaches to streamlining the ANDA review process. Second, the FDA will issue a “Good ANDA Submission Practices” guidance document that will detail common deficiencies that the agency sees in applications, and will provide advice on how to avoid these problems.
Following Gottlieb’s remarks, members of the public addressed a panel comprising representatives from the FDA and the Federal Trade Commission. Individuals representing academic and research, payer and provider, pharmaceutical product development, and patient and consumer perspectives provided comments to the panel.
Across the variety of stakeholder perspectives, some common themes and concerns emerged:
In closing the meeting, Keith Flanagan of the FDA’s Office of Generic Drugs and the Center for Drug Evaluation and Research, said that it will take the agency time to digest the information that it has received from the public, and that it will leverage the insights gained through public comment. In addition to considering presentations made at the meeting, the agency will also review comments made on the its docket.
Among those who have already submitted written comments to the docket are former Representative Henry Waxman, one of the co-sponsors of the original Hatch-Waxman legislation. Waxman's remarks include a report, “Getting to the Root of High Prescription Drug Prices,” that describes drivers of high prescription drug costs and potential actions that could be taken to address those costs. Among Waxman’s recommendations are that the FDA:
Electronic comments may be submitted on docket number FDA-2017-N-3615 until September 18, 2017.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.